María Garcés-Pellejero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
María Garcés-Pellejero has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Elena Fonseca
Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Spain
5 shared publications - Daniel Campos-Fernández
Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Spain
4 shared publications - Enric Bellido-Castillo
Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Spain
4 shared publications - Manuel Quintana
Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Spain
3 shared publications Manuel Toledo
Neurology Department, Epilepsy Unit, Vall d'Hebron University Hospital. Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, Barcelona, Spain
3 shared publicationsSamuel López-Maza
Neurology Department, Epilepsy Unit, Vall d'Hebron University Hospital. Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, Barcelona, Spain
3 shared publications
Latest Publications
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10)
Cenobamate in Focal-Onset Refractory and Super-Refractory Status Epilepticus
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10)
Cenobamate in Focal-Onset Refractory and Super-Refractory Status Epilepticus
- Open Access
- 24 July 2026
- Published by Elsevier in Neurología
- Vol. 41 (7)
Valor semiológico de los movimientos rítmicos ictales no clónicos de la mano (RINCH) en las crisis epilépticas
- 24 July 2026
- Published by Elsevier in Neurología
- Vol. 41 (7)
Open AccessValor semiológico de los movimientos rítmicos ictales no clónicos de la mano (RINCH) en las crisis epilépticas
- Open Access
- 25 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70654
Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis
Objectives: To compare response (reduction in headache frequency and differences in patient‐reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase‐IV trials after 6 months of treatment. Materials/Methods: A prospective cohort study included two parallel cohorts of chronic migraine patients treated with either Erenumab 140 mg/month or OnabotulinumtoxinA 195 U every 3 months. Participants had no additional preventive therapies or comorbid psychiatric or chronic pain conditions. Baseline data collected included demographics, monthly headache (MHD) and migraine days (MMD), impact scales (MIDAS, HIT‐6, MSQ), and anxiety/depression scores (BAI, BDI‐II). Assessments were repeated at 6 months. Baseline characteristics were balanced. Efficacy analysis (measured by reduction in MHD/MMD and impact scales) was conducted using paired t ‐test, and linear regression models compared treatment‐related changes between groups. Results: A total of 114 patients were analyzed (57 per group), with no significant baseline differences. Both treatments produced significant reductions in headache frequency at 6 months (Erenumab: −7.93 MHD and −5.36 MMD, p < 0.001; OnabotA: −6.00 MHD and −4.31 MMD, p < 0.001), without statistically significant differences between therapies. Significant improvements were observed in HIT‐6 and MSQ scores in both cohorts ( p < 0.05). The Erenumab group showed significant reductions in MIDAS, BDI, and BAI scores ( p < 0.05). Differences between treatments were significant for MIDAS improvements at three and 6 months ( p < 0.05). Conclusion: Erenumab and OnabotulinumtoxinA are effective preventive treatments for chronic migraine. No significant differences were found in the magnitude of headache reduction at 3 or 6 months when comparing both treatments.
- 25 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70654
Open AccessErenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis
Objectives: To compare response (reduction in headache frequency and differences in patient‐reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase‐IV trials after 6 months of treatment. Materials/Methods: A prospective cohort study included two parallel cohorts of chronic migraine patients treated with either Erenumab 140 mg/month or OnabotulinumtoxinA 195 U every 3 months. Participants had no additional preventive therapies or comorbid psychiatric or chronic pain conditions. Baseline data collected included demographics, monthly headache (MHD) and migraine days (MMD), impact scales (MIDAS, HIT‐6, MSQ), and anxiety/depression scores (BAI, BDI‐II). Assessments were repeated at 6 months. Baseline characteristics were balanced. Efficacy analysis (measured by reduction in MHD/MMD and impact scales) was conducted using paired t ‐test, and linear regression models compared treatment‐related changes between groups. Results: A total of 114 patients were analyzed (57 per group), with no significant baseline differences. Both treatments produced significant reductions in headache frequency at 6 months (Erenumab: −7.93 MHD and −5.36 MMD, p < 0.001; OnabotA: −6.00 MHD and −4.31 MMD, p < 0.001), without statistically significant differences between therapies. Significant improvements were observed in HIT‐6 and MSQ scores in both cohorts ( p < 0.05). The Erenumab group showed significant reductions in MIDAS, BDI, and BAI scores ( p < 0.05). Differences between treatments were significant for MIDAS improvements at three and 6 months ( p < 0.05). Conclusion: Erenumab and OnabotulinumtoxinA are effective preventive treatments for chronic migraine. No significant differences were found in the magnitude of headache reduction at 3 or 6 months when comparing both treatments.
- 5 June 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 140, 143-148
Delirium in critically ill patients treated with levetiracetam or brivaracetam: a comparative study
- 5 June 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 140, 143-148
Delirium in critically ill patients treated with levetiracetam or brivaracetam: a comparative study
- 9 May 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 181, 111090
Self-reported quality of life outcomes after Cenobamate initiation
- 9 May 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 181, 111090
Self-reported quality of life outcomes after Cenobamate initiation
- 5 April 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 180, 111028
Development of a deep learning tool to detect drug-resistance epilepsy with EEG
- 5 April 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 180, 111028
Development of a deep learning tool to detect drug-resistance epilepsy with EEG